Inhibition of nutlin-resistant HDM2 mutants by stapled peptides.
Pharmacological modulation of p53 activity is an attractive therapeutic strategy in cancers with wild-type p53. Presently in clinical trials, the small molecule Nutlin-3A competitively binds to HDM2, a key negative regulator of p53 and blocks its activity. We have described resistance mutations in H...
| Published in: | PLoS ONE |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Online Access: | http://europepmc.org/articles/PMC3835680?pdf=render |